Navigation Links
LSUHSC awarded patent for compound inhibiting cancer and other diseases

New Orleans, LA Dr. Eugene Woltering, the James D. Rives Professor of Surgery and Neurosciences at LSU Health Sciences Center New Orleans School of Medicine, and Dr. Conrad Hornick, former LSUHSC Professor of Physiology, have been awarded a US Patent for a compound to inhibit the formation of blood vessels critical to the growth of cancerous tumors and diseases like diabetic retinopathy, obesity, and psoriasis.

Apolipoprotein A-I is the major protein component of lipoproteins water soluble carrier molecules that transport cholesterol through the blood. LSUHSC researchers discovered that it can be used to destroy existing blood vessels as well as prevent the development of new vessels. For a tumor to grow bigger than 2 mm, the diameter of a large grain of sand, it must a have blood supply. Application of Apoliporpotein A-1 and high density lipoprotein has been proven effective in inhibiting tumor growth dependent upon angiogenesisthe process of developing new blood vessels. Studies have demonstrated that the level of vascularization in a tumor is strongly associated with metastasis in melanoma, breast, and lung carcinomas.

"This patent was based on the observation that lipid droplets are critical to the formation of the lumen of the blood vessels. By removing these fat droplets from the developing blood vessel we feel that we will be able to control the growth of new blood vessels that would feed tumors," notes Dr. Woltering.

There is also evidence that Apolipoprotein A-1 will be effective in treating other diseases reliant upon angiogenesis. In those diseases, angiogenesis is the root cause of tissue injury, including blindness associated with proliferative retinopathies, skin disorders such as psoriasis, and rheumatoid arthritis. Diseases that have been associated with abnormal blood vessel formation include Crohn's disease, diabetic retinopathy, macular degeneration, obesity, corneal neovascularization, benign tumors, hemangioma, arterial/venous malformations, sickle cell anemia, sarcoidosis, syphilis, pseudoxanthoma elasticum, Pagets disease, vein occlusion in the eye, infections of the retina, hyperparathyroidism, carotid obstructive disease, chronic uveitis/vitritis, mycobacterial infections, Lyme disease, systemic lupus erythematosis, psoriasis, myopia, optic pits, Stargarts disease, chronic retinal detachment, hyperviscosity syndrome, toxoplasmosis, trauma, rheumatoid arthritis, and post-laser complications.


Contact: Leslie Capo
Louisiana State University Health Science Center

Related biology news :

1. LSUHSC awarded $10M+ COBRE grant
2. LSUHSCs Lazartigues awarded $1.2 million grant
3. LSUHSC research reports new method to protect brain cells from diseases like Alzheimers
4. 12 McGill researchers awarded Canada Research Chairs
5. Anthony S. Fauci awarded Lasker Award for Public Service
6. ETH Zurich professor Ari Helenius awarded Benoist Prize
7. Nanobiosym awarded $2 million DTRA contract
8. Mustafa alAbsi Ph.D. and national team awarded major NIH grant
9. Parus Interactive Awarded Patent for Speech-Activated Remote System Management
10. $2.7 million awarded for metastatic colon cancer research
11. UCR researchers awarded nearly $1.7M to develop improved cowpea varieties
Post Your Comments:
(Date:11/18/2015)...  As new scientific discoveries deepen our understanding of ... providers face challenges in better using that knowledge to ... as more children continue to survive pediatric cancer, that ... age. John M. Maris, M.D ., a ... (CHOP) . --> John M. Maris, ...
(Date:11/17/2015)... Mass. , Nov. 17, 2015 Pressure ... leader in the development and sale of broadly enabling, ... worldwide life sciences industry, today announced it has received ... its $5 million Private Placement (the "Offering"), increasing the ... $4,025,000.  One or more additional closings are expected in ...
(Date:11/11/2015)... Minn. , Nov. 11, 2015   MedNet Solutions ... entire spectrum of clinical research, is pleased to announce that ... in Clinical Trials (PCT) event, to be held November ... be able to view live demonstrations of iMedNet ... and learn how iMedNet has been able to ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. ... (Nasdaq: HART ), a biotechnology company developing bioengineered ... Jim McGorry will present at the LD ... 2015 at 2:30 p.m. PT. The presentation will be ... 30 days. Management will also be available at the ...
(Date:11/25/2015)... Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... business and prospects remain fundamentally strong and highlights ... doxorubicin) recently received DSMB recommendation to continue the ... review of the final interim efficacy and safety ... Endpoint in men with heavily pretreated castration- and ...
(Date:11/25/2015)... -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) today ... discussion at the Piper Jaffray 27th Annual Healthcare Conference ... is scheduled for Wednesday, December 2, at 8:00 a.m. ... will be available for 14 days after the event.  ... Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... uBiome, were featured on AngelList early in their initial angel funding process. Now, ... syndicate for individuals looking to make early stage investments in the microbiome space. ...
Breaking Biology Technology: